Our Leadership

Robert Greif

Chief Executive Officer

Robert Greif is Chief Executive Officer and President of H-CYTE. Greif brings to H-CYTE a strong track record leading high-growth pharmaceutical and biotech businesses, having successfully taken more than a dozen products from discovery to commercialization.

“I am honored to be joining the H-CYTE team to innovate and implement novel growth strategies in our biologics development,” said Greif in a statement. “With a focus on evidence-based medicine, it is my hope for H-CYTE to immediately begin clinical research and development of a diverse pipeline of next-generation regenerative therapeutics to meet the needs of patients with a variety of diseases and chronic health conditions.”

Prior to joining H-CYTE, Greif was Chief Commercial Officer and Business Development Leader at Atox Bio, where he built the North American commercial organization in preparation for the launch of a first-in-class immunomodulator. Prior to that, he led the Commercial Operations of rEVO Biologics, an orphan disease biotechnology company. He has also held a variety of business unit and commercial leadership roles at United health Group, Boehringer Ingelheim and Sanofi SA.

Jeremy Daniel

Chief Financial Officer

Jeremy Daniel is highly experienced with financial, operations and strategic planning in an executive capacity. Daniel has broad-based expertise building and leading effective strategies for revenue production, operations management, team leadership and financial and accounting systems in the health care industry.

Since 2012, Daniel has served as the CFO of H-CYTE, where he co-leads vision, strategy and execution of all facets of financial, operations, strategic planning and organizational development. Daniel earned a bachelor’s degree in business administration from the University of Cincinnati and an MBA from Xavier University.